Today: 3 February 2026
Subscribe
Browse Category

Analyst Forecasts News 2 December 2025 - 4 December 2025

Bayer Aktie Soars After U.S. Roundup Breakthrough: Latest News, Analyst Forecasts and 2026 Outlook (4 December 2025)

Bayer Aktie Soars After U.S. Roundup Breakthrough: Latest News, Analyst Forecasts and 2026 Outlook (4 December 2025)

Bayer’s share price has exploded higher in early December 2025 after the U.S. government unexpectedly sided with the company in its long‑running Roundup legal saga. For investors in Bayer Aktie (BAYN, BAYGN.DE, BAYRY), the move has transformed sentiment almost overnight – but the underlying story is still a complex mix of litigation risk, heavy debt, restructuring and a slowly improving pipeline.…
4 December 2025
··
Arbe Robotics (ARBE) Stock: Q3 2025 Earnings, Analyst Forecasts and Radar Growth Story – Updated December 4, 2025

Arbe Robotics (ARBE) Stock: Q3 2025 Earnings, Analyst Forecasts and Radar Growth Story – Updated December 4, 2025

Arbe Robotics Ltd. (NASDAQ: ARBE), the Israeli 4D imaging radar specialist, is back on traders’ screens after a sharp rebound in its share price, fresh awards for its technology, and a mixed Q3 2025 earnings report that highlights both progress and persistent risk. As of December 4, 2025, ARBE trades around $1.57 per share after a 14.6% jump in Wednesday’s…
4 December 2025
···
Haleon PLC (HLN) Stock on December 4, 2025: Price, Latest News, Analyst Targets and 2026 Outlook

Haleon PLC (HLN) Stock on December 4, 2025: Price, Latest News, Analyst Targets and 2026 Outlook

Updated: December 4, 2025 Haleon PLC – the consumer‑health group behind Sensodyne, Voltaren, Advil, Panadol and Centrum – is ending 2025 in a strangely paradoxical place: the business is grinding out steady growth and strong cash flow, while the share price has been drifting lower in recent weeks. As of early trading on December 4, 2025, Haleon’s New York‑listed ADR…
4 December 2025
····
Rolls-Royce Holdings plc Stock on 4 December 2025: Share Price, Analyst Forecasts and 2026 Outlook

Rolls-Royce Holdings plc Stock on 4 December 2025: Share Price, Analyst Forecasts and 2026 Outlook

Rolls-Royce Holdings plc (LON: RR, OTC: RYCEY) goes into the final weeks of 2025 as one of the standout names on the FTSE 100, with the share price still close to record highs and debate intensifying over how much upside is left. As trading closed in London on 4 December 2025, Rolls-Royce shares were quoted at 1,067.5p (sell price) and…
4 December 2025
····
3i Group plc Stock Near 52‑Week Lows After Action Warning – Latest News, Analyst Forecasts and Outlook (4 December 2025)

3i Group plc Stock Near 52‑Week Lows After Action Warning – Latest News, Analyst Forecasts and Outlook (4 December 2025)

Updated: 4 December 2025 3i Group share price on 4 December 2025 3i Group plc (LON: III), the FTSE 100 private equity and infrastructure investor, remains under pressure in early December after a sharp sell‑off triggered by concerns over growth at its flagship investment, European discount retailer Action. In London trading on 4 December 2025, 3i shares were quoted around…
4 December 2025
····
Synopsys (SNPS) Stock on December 3, 2025: Nvidia’s $2 Billion Bet, Class‑Action Lawsuits and New Analyst Forecasts

Synopsys (SNPS) Stock on December 3, 2025: Nvidia’s $2 Billion Bet, Class‑Action Lawsuits and New Analyst Forecasts

Synopsys, Inc. (NASDAQ: SNPS) is back in the market spotlight after a volatile few months. On Wednesday, December 3, 2025, the stock extended a sharp rebound driven by Nvidia’s $2 billion strategic investment, even as fresh class‑action lawsuits and mixed analyst messages kept risks firmly on the radar. As of the U.S. close on December 3, Synopsys shares were trading…
3 December 2025
···
SoFi Technologies (SOFI) Stock Today: December 3, 2025 Price, News, Analyst Forecasts and S&P 500 Hopes

SoFi Technologies (SOFI) Stock Today: December 3, 2025 Price, News, Analyst Forecasts and S&P 500 Hopes

Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) are back in the spotlight on December 3, 2025, as new analyst commentary, big institutional buys and talk of future S&P 500 inclusion collide with an already‑huge six‑month rally in the stock. Below is a comprehensive, news‑style rundown of today’s price action, the latest headlines, Wall Street forecasts and key risks investors are…
3 December 2025
····
Credo Technology Group (CRDO) Stock Soars on Record AI Earnings: Latest News, Analyst Forecasts & Outlook as of December 3, 2025

Credo Technology Group (CRDO) Stock Soars on Record AI Earnings: Latest News, Analyst Forecasts & Outlook as of December 3, 2025

Credo Technology Group Holding Ltd (NASDAQ: CRDO) has become one of 2025’s standout AI infrastructure plays. After a blowout fiscal Q2 2026 report and a wave of analyst upgrades, the stock is trading around $183 per share on December 3, 2025, having surged well into triple‑digit gains for the year. MarketWatch This article pulls together all the key news, earnings…
3 December 2025
····
Fortis Inc. (TSX: FTS) Stock on December 3, 2025: Latest News, Dividend Hike and 2026 Analyst Forecast

Fortis Inc. (TSX: FTS) Stock on December 3, 2025: Latest News, Dividend Hike and 2026 Analyst Forecast

Tickers: TSX: FTS, NYSE: FTS – Data as of the morning of December 3, 2025. This article is for information only and is not investment advice. Quick take: what’s happening with Fortis stock today? On December 3, 2025, Fortis Inc. stock is trading near the top of its 52‑week range after breaking decisively above its 200‑day moving average on the…
3 December 2025
···
Intertek Group plc (LON: ITRK) Stock on 3 December 2025: Price, Trading Update, Analyst Targets and 2026 Outlook

Intertek Group plc (LON: ITRK) Stock on 3 December 2025: Price, Trading Update, Analyst Targets and 2026 Outlook

As of the close on 3 December 2025, Intertek Group plc (LON: ITRK) – the FTSE 100 testing, inspection and certification specialist – is trading around 4,610p per share, leaving the stock roughly 2% lower than a year ago and well below its 52‑week high but comfortably above its spring low. FT Markets The company has spent the past few…
3 December 2025
···
Marks & Spencer (MKS.L) Stock Update: Price Action, Outlook and Analyst Forecasts – 3 December 2025

Marks & Spencer (MKS.L) Stock Update: Price Action, Outlook and Analyst Forecasts – 3 December 2025

Marks and Spencer Group plc stock is back in the spotlight after a profit hit from a cyberattack, a fresh Christmas marketing push – and a headline-grabbing long‑term analyst call of 705p per share. Key facts at the close on 3 December 2025 Performance-wise, data from Hargreaves Lansdown and StockAnalysis shows M&S shares are modestly negative year‑to‑date in 2025 (around…
3 December 2025
····
IonQ Stock (IONQ) in December 2025: Latest News, Analyst Forecasts, and Quantum Computing Risks Investors Need to Know

IonQ Stock (IONQ) in December 2025: Latest News, Analyst Forecasts, and Quantum Computing Risks Investors Need to Know

IonQ, Inc. (NYSE: IONQ) remains one of the most closely watched pure‑play quantum computing stocks as of December 2, 2025. After a year of extreme volatility, the shares are trading around $47–48 per share, with an intraday range between roughly $46.8 and $49.2 and heavy trading volume. TS2 Tech The stock is still dramatically higher than it was a year…
2 December 2025
····
1 … 40 41 42 43

Stock Market Today

  • Market Jitters on Lilly Earnings, Hopeful Signs for Housing Stocks
    February 3, 2026, 3:57 PM EST. Stocks dipped Tuesday as tech selloff pressured the S&P 500 and Nasdaq, with Nvidia down over 3%, despite CEO Jensen Huang dismissing rift rumors with OpenAI. Eli Lilly shares fell nearly 4% ahead of earnings, weighed by rival Novo Nordisk's poor 2026 sales and profit forecast amid U.S. price pressures and rising competition. Investors question if Lilly's volume growth from expanded patient access will offset declining drug prices. Meanwhile, housing stocks like Lennar and Taylor Morrison rallied on reports of a private investor-backed plan to increase entry-level home affordability, though the Trump administration has no active involvement, indicating early-stage talks. The market balances caution on pharma earnings with cautious optimism on housing initiatives.
Go toTop